BioMarin Pharmaceutical Inc.

Total Valuation

BioMarin Pharmaceutical Inc. carries a market capitalization of 12.86B, placing it among publicly traded companies globally. Its enterprise value stands at 14.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

BioMarin Pharmaceutical Inc. currently has 193.28M shares outstanding.

Valuation Ratios

BioMarin Pharmaceutical Inc. trades at a trailing price-to-earnings ratio of 150.98. The price-to-sales ratio is 3.23, and the price-to-book ratio stands at 1.75.

Enterprise Valuation

On an enterprise value basis, BioMarin Pharmaceutical Inc. trades at an EV/EBITDA multiple of 47.60 and an EV/FCF ratio of 14.04. The EV/Sales ratio of 4.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 96.36 provides insight into valuation relative to core operating earnings.

Financial Position

BioMarin Pharmaceutical Inc. maintains a current ratio of 2.39, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.47, indicating elevated leverage, while an interest coverage ratio of 3.62 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

BioMarin Pharmaceutical Inc. posts a return on equity of 1.18 and a return on invested capital of 0.85.

Taxes

Over the trailing twelve months, BioMarin Pharmaceutical Inc. has paid 76.14M in income taxes, reflecting an effective tax rate of 51.06.

Stock Price Statistics

BioMarin Pharmaceutical Inc.'s stock has gained approximately 15.16358% over the past 52 weeks. The 50-day moving average sits at 62.39, while the 200-day moving average is 57.79.

Income Statement

Over the trailing twelve months, BioMarin Pharmaceutical Inc. generated 3.41B in revenue and converted that into 72.97M in net income, yielding earnings per share of 0.38. EBITDA reached 302.29M, while operating income came in at 149.32M.

Balance Sheet

BioMarin Pharmaceutical Inc. holds 874.01M in cash and equivalents against 4.20B in total debt, resulting in a net debt position of 3.31B. Total book value stands at 6.32B, with working capital of 2.31B providing operational flexibility.

Cash Flow

BioMarin Pharmaceutical Inc. produced 857.09M in operating cash flow over the past twelve months. After subtracting -126.58M in capital expenditures, free cash flow totaled 730.51M - equivalent to 3.79 per share.

Margins

BioMarin Pharmaceutical Inc. operates with a gross margin of 76.12, reflecting its pricing power and cost economics. The operating margin of 4.38 and net profit margin of 2.14 provide insight into operational efficiency.

Dividends & Yields

Scores

BioMarin Pharmaceutical Inc. posts an Altman Z-Score of 2.37, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.